List view / Grid view
17 December 2020 | By Living Systems Institute, University of Exeter
Watch our on-demand webinar where we explore new methods to improve data quality from high-throughput screens. You'll learn about solutions for common problems in drug-target discovery and our keynote speaker will also look at case studies where new approaches to screening have identified high-quality candidate drugs for proliferative diseases.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Scientists have trained a computer algorithm to identify differences in cancer cell lines based on microscopic images, preventing the misclassification of cells.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Study shows that haematoxylin can selectively kill cancers with a mutated form of the calreticulin gene (CALR), common in a group of bone marrow cancers called myeloproliferative neoplasms (MPNs).
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
This article provides a brief overview of the technical and conceptual advantages of Raman spectroscopy, a label-free imaging technique that is being increasingly used for the purpose of drug evaluation.
The use of genetic testing has had a positive impact on patient care, bringing abundant opportunities for diagnosis or predictions of future diagnoses. Pushpanathan Muthuirulan explains how the application of genetic screening can help to customise healthcare for individuals based on their unique genetic makeup.
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
Researchers at Ingenza and the University of Plymouth are using a machine learning and high‑throughput screening approach to discover novel antimicrobial therapies. In this article, Nikki Withers spoke to one of the researchers, Jack Kay, to hear about the current threat posed by antimicrobial resistance and how he hopes their…
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
